Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer

Curr Pharm Biotechnol. 2022;23(15):1788-1791. doi: 10.2174/1389201023666220307090450.
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Capecitabine / therapeutic use
  • Fluorouracil / therapeutic use
  • Humans
  • Pancreatic Neoplasms* / drug therapy
  • Treatment Outcome

Substances

  • Capecitabine
  • Fluorouracil